Healthcare (SH:603313)2023-04-28 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥1,698,777,486.14, a decrease of 20.74% compared to the same period last year[4] - Net profit attributable to shareholders was ¥16,773,452.09, down 45.58% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥5,231,205.32, a decline of 81.18% compared to the previous year[4] - Basic earnings per share decreased by 50.00% to ¥0.03[4] - Total operating revenue for Q1 2023 was ¥1,698,777,486.14, a decrease of 20.7% compared to ¥2,143,312,803.14 in Q1 2022[19] - Net profit for Q1 2023 was ¥19,637,876.76, a decline of 44.5% from ¥35,398,174.00 in Q1 2022[20] - The total comprehensive income for Q1 2023 was ¥19,084,294.11, compared to ¥20,708,300.62 in Q1 2022, reflecting a decrease of 7.8%[20] - The total comprehensive income attributable to the parent company for Q1 2023 was ¥18,932,005.43, an increase from ¥14,582,882.34 in Q1 2022, representing a growth of approximately 29.5%[21] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 279.94% to ¥192,692,648.06[4] - Net cash flow from operating activities for Q1 2023 was ¥192,692,648.06, a significant improvement compared to a negative cash flow of ¥107,088,289.77 in Q1 2022[21] - Cash inflow from operating activities totaled ¥1,812,006,275.96 in Q1 2023, down 18.9% from ¥2,235,418,738.81 in Q1 2022[21] - Cash outflow from operating activities was ¥1,619,313,627.90 in Q1 2023, a decrease of 30.9% compared to ¥2,342,507,028.58 in Q1 2022[21] - The net cash flow from investing activities was -¥22,595,342.46 in Q1 2023, an improvement from -¥140,500,602.76 in Q1 2022[22] - Cash flow from financing activities showed a net outflow of -¥217,932,700.42 in Q1 2023, compared to a net inflow of ¥97,735,651.56 in Q1 2022[22] - The ending balance of cash and cash equivalents as of the end of Q1 2023 was ¥399,497,768.27, down from ¥608,589,835.27 at the end of Q1 2022[22] - The company's cash and cash equivalents stood at RMB 496,087,473.36, down from RMB 555,096,755.63 at the end of 2022, indicating a decrease of about 10.63%[14] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,186,259,104.62, an increase of 1.22% from the end of the previous year[5] - The total liabilities as of Q1 2023 amounted to ¥6,101,610,311.98, an increase from ¥6,014,473,347.87 in the previous year[17] - Total assets decreased to $9,075,676,576.56 from $9,423,077,093.43, a reduction of approximately 3.68%[25] - Total liabilities decreased to $6,014,473,347.87 from $6,357,512,594.90, reflecting a decline of about 5.39%[26] - Non-current liabilities totaled $2,090,289,983.33, down from $2,433,329,230.36, indicating a decrease of approximately 14.09%[26] - Current liabilities totaled $3,924,183,364.54, remaining unchanged from the previous period[25] Equity and Shareholder Information - The company's equity attributable to shareholders was ¥3,004,056,669.17, reflecting a growth of 0.88% compared to the previous year[5] - The total equity attributable to shareholders was ¥3,004,056,669.17, up from ¥2,977,841,262.92 in Q1 2022[17] - Owner's equity totaled $3,061,203,228.69, slightly down from $3,065,564,498.53, a decrease of about 0.14%[26] Operational Efficiency - The company's gross profit margin for Q1 2023 was approximately 0.65%, compared to 0.33% in Q1 2022[19] - Total operating costs for Q1 2023 were ¥1,687,465,327.40, down from ¥2,072,276,176.03 in Q1 2022, reflecting a reduction of 18.6%[19] - Research and development expenses for Q1 2023 were ¥20,620,160.92, a decrease of 23.5% from ¥27,016,719.14 in Q1 2022[19] - The company reported a decrease in sales expenses to ¥342,430,268.46 in Q1 2023 from ¥296,984,844.58 in Q1 2022, indicating a rise of 15.3%[19] - The company’s financial expenses increased to ¥103,411,114.13 in Q1 2023, compared to ¥65,361,104.51 in Q1 2022, marking a rise of 58.2%[19] Legal and Regulatory Matters - The company has a pending lawsuit involving a claim for USD 3.1225 million related to a breach of contract, with potential liabilities recognized at RMB 118,702,442.39[13] - The company is involved in ongoing litigation with a potential impact on its financial position, with the outcome currently uncertain[12] - The company continues to focus on maintaining its market position and exploring new strategies for growth amid ongoing legal challenges[11] - The company plans to implement new accounting standards starting January 1, 2023, which may affect future financial reporting[22] Asset Composition - Accounts receivable increased to RMB 1,374,858,649.35 from RMB 1,341,588,741.25, representing a rise of approximately 2.47%[15] - Inventory levels were reported at RMB 1,737,676,411.47, slightly up from RMB 1,729,612,707.99, showing a marginal increase of about 0.42%[15] - The company's non-current assets totaled RMB 5,304,156,848.83, compared to RMB 5,173,823,807.01 at the end of 2022, marking an increase of approximately 2.53%[15] - Short-term borrowings were recorded at RMB 1,650,340,583.95, a slight decrease from RMB 1,661,596,964.84, reflecting a reduction of about 0.88%[15] - The company reported a significant increase in deferred tax assets, which rose to RMB 542,425,315.39 from RMB 209,703,019.40, indicating a growth of approximately 158.80%[15]